Cybin Therapeutics

The BC Bud Corporation (OTCQB: BCBCF) (CSE:BCBC) has closed an initial tranche of its non-brokered private placement. Gross proceeds of $52,500 were raised through the sale of 700,000 units at a price of $0.075 per unit. Each unit comprised one common share and one share purchase warrant. Each...

Psyence Group (OTCQB: PSYGF) and Filament Health Corp. (OTCQB: FLHLF) announced the signing of a licensing agreement: Filament is to license its proprietary psilocybin derived drug, PEX010, and the associated IP to Psyence for use in its upcoming clinical trials. Thanks to this license,...